Can Placenta Cells Save Severe COVID-19 Patients?

Pluristem CEO Claims Placenta Cell-Therapy Can Rebalance Immune Systems

20 Apr 2020

• By Sten Stovall

Pluristem Therapeutics aims to start a multinational clinical trial of PLX cells for treating complications associated with COVID-19 while also helping severe patients recover from the disease under compassionate use programs in the US and Israel.

Yaky Yanay — Pluristem CEO Yanay wants to test his product ASAP in COVID-19 patients • Source: Pluristem Therapeutics Inc.

Stem cells from a newborn’s placenta could potentially heal lung tissue in severe-case COVID-19 patients by rebalancing their immune system, says Israeli firm Pluristem Therapeutics Inc.. The premise has already been successfully applied in individual cases in Israel and the US and will soon be formally studied in a multinational clinical trial, its CEO told Scrip.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

01 May 2025

• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

01 May 2025

• By Andrew McConaghie

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.